LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Europe’s Rare Disease SMEs raise their voice for success

25/04/2023

NEWS RELEASE

Brussels, 25 April 2023 - On February 28th 2023, Rare Disease Day, EuropaBio's Small and Medium-sized Enterprises (SME) Platform hosted a session on rare diseases and invited European SMEs to share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislations on orphan and paediatric medicines. Participants discussed Research and Development, Regulation, and the European Market and investment environment.

 

Science, Research and Development

Each rare disease affects a small number of people, which brings significant challenges in clinical trial design and recruitment, alongside the limited knowledge of the overall clinical evidence and disease progression process.

Participants discussed the importance of data sharing and patient registries to fill information gaps and the European Medicines Agency's essential support in protocol assistance and scientific advice.

 

Regulatory frameworks

Smaller companies discussed the concept of unmet medical needs and why it must stay broader, allowing to guide investment in areas with fewer therapeutic options and where scientific developments are more promising. Participants discussed some of the challenges and considerations for market launch in Europe and how they can't do it in all 27 Member States. Challenges include the lack of rare disease patients in some countries, country-specific requirements (e.g., the need for pharmacovigilance departments) and the lack of specialized care centres able to administer complex new treatments.

 

Market and investment environment

As national healthcare structures evolve, new technologies are adopted, public awareness increases, and information is improved, more rare disease patients will be diagnosed, creating additional financial pressure in an already underfunded sector.

Smaller companies face a challenging financial environment and struggle to raise investment from public and private partners to finance their products' research and development. They must have a predictable legal framework to make informed long-term decisions and be able to raise external capital to address the EU's market fragmentation.

 

Please consult our event report for our session's conclusion and SME recommendations.

Rare diseases – SME BioForum report 2023


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
05/06/2025

The GPL must include biotech & life science to unleash EU innovation


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.